What is your approach to immune management in opsoclonus-myoclonus-ataxia syndrome?

I believe immunotherapy for OMAS and all neuroinflammatory diseases should always be individualized to the specific patient, ideally with input from a neuroimmunologist when possible. My practice closely follows the OMAS International Working Group consensus published in 2022 (Rossor et al., PMID 35...